ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,116.17
0.00%
US Tech 100
17,286.78
-0.13%
다우존스 지수
38,386.09
0.00%
Bitcoin
61,174.76
-4.17%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Alterity Therapeutics Limited (ATHE)

  7. Alterity Therapeutics Limited (ATHE) 뉴스

ATHE Alterity Therapeutics Limited

2.19
-0.005 (-0.23%)
시간외 단일가
최종 업데이트: 21:17:24
15분 지연
기업명 주식 심볼 시장 주식 타입
Alterity Therapeutics Limited ATHE 나스닥 주식예탁증서 (DR)
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
-0.005 -0.23% 2.19 21:17:24
개장가 저가 고가 종가 전일 종가
2.195
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
30/04/202420:25GLOBEAppendix 4C – Q3 FY24 Quarterly Cash Flow Report
29/04/202420:25GLOBEAlterity Therapeutics Presents New Data Demonstrating..
17/04/202420:25GLOBEAlterity Therapeutics Parkinson’s Disease and Multiple..
10/04/202420:25GLOBEAlterity Therapeutics to Present New Data on ATH434 at the..
26/03/202423:25GLOBEAlterity Therapeutics Receives a A$3.9 Million Research &..
21/02/202400:25GLOBEAlterity Therapeutics to Present New Data at the Upcoming..
16/02/202407:29EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/02/202407:28EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/02/202421:25GLOBEAlterity Therapeutics Phase 2 Data Monitoring Committee..
31/01/202422:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/01/202421:24GLOBEAlterity Therapeutics to Participate in the ShareCafe Hidden..
22/01/202421:25GLOBEAlterity Therapeutics Issues Shareholder Letter Highlighting..
22/01/202420:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/01/202422:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/01/202407:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/01/202407:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/01/202420:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/01/202422:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/01/202422:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/01/202422:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/01/202422:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/01/202420:27EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/01/202420:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/01/202422:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/01/202422:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/01/202422:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/12/202322:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/12/202322:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202322:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202322:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202314:30GLOBEAlterity Therapeutics Appoints Phillip Hains as Chief..
05/12/202306:35GLOBEAlterity Therapeutics to Host Webcast to Discuss ATH434..
04/12/202321:25GLOBEAlterity Therapeutics Reports Positive Efficacy Data for..
27/11/202321:25GLOBEAlterity Therapeutics Announces Presentation of Novel..
16/11/202321:25GLOBEAlterity Therapeutics Announces Presentation of New Data..
08/11/202321:25GLOBEAlterity Therapeutics Completes Enrolment in ATH434-201..
30/10/202320:25GLOBEAppendix 4C – Q1 FY24 Quarterly Cash Flow Report
26/10/202313:15EDGAR2Form EFFECT - Notice of Effectiveness
13/09/202319:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/08/202320:25GLOBEAlterity Therapeutics Presents New Data on Multiple System..
23/08/202320:25GLOBEAlterity Therapeutics Granted New Composition of Matter..
22/08/202320:25GLOBEAlterity Therapeutics Rare Disease Natural History Study to..
15/08/202320:25GLOBEAlterity Therapeutics Receives a $4.74 million Research &..
31/07/202320:52GLOBEAppendix 4C – Q4 FY23 Quarterly Cash Flow Report
26/07/202320:25GLOBEAlterity Therapeutics Phase 2 Data Monitoring Committee..
21/06/202320:25GLOBEAlterity Therapeutics to Present in MST Access Rare..
30/05/202320:25GLOBEAlterity Therapeutics Initiates Second Phase 2 Study in Rare..
19/05/202320:25GLOBEAlterity Therapeutics CEO David Stamler to Present at the..
10/05/202320:25GLOBEAppendix 4C – Q3 FY23 Quarterly Cash Flow Report

최근 히스토리

NASDAQ
ATHE
Alterity Therapeutics
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유